Use of lacosamide in children: experience of a tertiary medical care center in Brazil
Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 y...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Academia Brasileira de Neurologia (ABNEURO)
2022-11-01
|
Series: | Arquivos de Neuro-Psiquiatria |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1758366 |